2021
Chapter 43 HIV and Other Retroviral Infections of the Nervous System
Peluso M, Spudich S. Chapter 43 HIV and Other Retroviral Infections of the Nervous System. 2021, 765-784. DOI: 10.1016/b978-0-12-819306-8.00043-5.Peer-Reviewed Original ResearchAntiretroviral therapyHIV infectionNeurologic manifestationsHuman immunodeficiency virus (HIV) infectionEra of ARTSuccessful systemic treatmentImmunodeficiency virus infectionEarly HIV infectionSystemic immune systemQuality of lifeAdvanced immunosuppressionAntiretroviral statusNeurologic complicationsNeurologic presentationSystemic treatmentVirus infectionCNS effectsCognitive disordersNervous systemImmune systemInfectionRetroviral infectionComplicationsHIVTherapy
2020
Selective Decay of Intact HIV-1 Proviral DNA on Antiretroviral Therapy
Gandhi R, Cyktor J, Bosch R, Mar H, Laird G, Martin A, Collier A, Riddler S, Macatangay B, Rinaldo C, Eron J, Siliciano J, McMahon D, Mellors J, Hogg E, LeBlanc R, Scello C, Palm D, Gandhi M, Fletcher C, Podany A, Aweeka F, Halvas L, Dragavon J, Joseph J, Lagattuta R, Lin L, Pederson S, Robertson K, Rubin L, Smith D, Spudich S, Tsibris A. Selective Decay of Intact HIV-1 Proviral DNA on Antiretroviral Therapy. The Journal Of Infectious Diseases 2020, 223: 225-233. PMID: 32823274, PMCID: PMC7857155, DOI: 10.1093/infdis/jiaa532.Peer-Reviewed Original ResearchConceptsTotal HIV-1 DNAResidual plasma viremiaAntiretroviral therapyHIV-1 DNAProvirus levelsPlasma viremiaLong-term antiretroviral therapyDefective HIV-1 provirusesHIV-1 proviral DNAReplication-competent reservoirSuppressive antiretroviral therapyMarkers of inflammationReplication-competent provirusesHIV-1 provirusART initiationImmune activationHIV-1Proviral DNATime pointsInfected cellsViremiaDefective provirusesInflammationTherapyProvirus
2019
Exosomal MicroRNAs Associate With Neuropsychological Performance in Individuals With HIV Infection on Antiretroviral Therapy.
OʼMeara T, Kong Y, Chiarella J, Price RW, Chaudhury R, Liu X, Spudich S, Robertson K, Emu B, Lu L. Exosomal MicroRNAs Associate With Neuropsychological Performance in Individuals With HIV Infection on Antiretroviral Therapy. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2019, 82: 514-522. PMID: 31714431, PMCID: PMC6857839, DOI: 10.1097/qai.0000000000002187.Peer-Reviewed Original ResearchConceptsCombination antiretroviral therapyNeuropsychological performanceAntiretroviral therapyViral suppressionHIV infectionNeurocognitive dysfunctionExo-miRNAsEarly infection groupCentral nervous systemSystemic viral suppressionTyrosine receptor kinaseInfection groupChronic infectionPLWHCross-sectional examinationNervous systemEarly infectionNeuropsychological scoresInfectionConsistent findingNeuropsychological batteryHIVNeurodegeneration pathwaysDysfunctionTherapyHIV persistence in the central nervous system during antiretroviral therapy: evidence and implications.
Spudich S, Clements JE. HIV persistence in the central nervous system during antiretroviral therapy: evidence and implications. AIDS 2019, 33 Suppl 2: s103-s106. PMID: 31789813, DOI: 10.1097/qad.0000000000002439.Peer-Reviewed Original ResearchMarkers of CNS Injury in Adults Living With HIV With CSF HIV Not Detected vs Detected <20 Copies/mL
Farhadian SF, Mistry H, Kirchwey T, Chiarella J, Calvi R, Chintanaphol M, Patel P, Landry ML, Robertson K, Spudich SS. Markers of CNS Injury in Adults Living With HIV With CSF HIV Not Detected vs Detected <20 Copies/mL. Open Forum Infectious Diseases 2019, 6: ofz528. PMID: 31893212, PMCID: PMC6934883, DOI: 10.1093/ofid/ofz528.Peer-Reviewed Original ResearchAntiretroviral therapyHIV RNACerebrospinal fluidBlood-brain barrier integrityCentral nervous system pathologyCNS immune activationCSF HIV RNANervous system pathologyCSF HIVCSF RNAImmune activationCNS injuryCopies/Neuropsychological testingSystem pathologyBarrier integrityCNS parametersHIVStandard assayExecutive functionRNAInjuryTherapySignificance of RNAPathologyPP 4.10 A modified TZM-bl assay (MoCo-TZA) documents replication-competent HIV in circulating monocytes despite 2 years of antiretroviral therapy initiated early during acute infection
Mitchell B, Laws E, Paul R, Vasan S, Kroon E, Valcour V, Spudich S, Shikuma C, Ananworanich J, Ndhlovu L. PP 4.10 A modified TZM-bl assay (MoCo-TZA) documents replication-competent HIV in circulating monocytes despite 2 years of antiretroviral therapy initiated early during acute infection. Journal Of Virus Eradication 2019, 5: 35-36. DOI: 10.1016/s2055-6640(20)30167-9.Peer-Reviewed Original ResearchDefining cerebrospinal fluid HIV RNA escape: editorial review AIDS.
Winston A, Antinori A, Cinque P, Fox HS, Gisslen M, Henrich TJ, Letendre S, Persaud D, Price RW, Spudich S. Defining cerebrospinal fluid HIV RNA escape: editorial review AIDS. AIDS 2019, 33 Suppl 2: s107-s111. PMID: 31790376, DOI: 10.1097/qad.0000000000002252.Peer-Reviewed Original Research
2018
Global Health Neurology: HIV/AIDS
Patel PB, Spudich SS. Global Health Neurology: HIV/AIDS. Seminars In Neurology 2018, 38: 238-246. PMID: 29791950, DOI: 10.1055/s-0038-1649334.Peer-Reviewed Original ResearchConceptsNeurologic complicationsLong-term HIVCombination antiretroviral therapyImpact of HIVResource-limited settingsHIV/AIDSAntiretroviral therapyOpportunistic infectionsCerebrovascular diseaseNeurocognitive disordersHIVMortality rateMajority of studiesComplicationsInternational studiesTherapyInfectionPrevalenceAIDSDiseaseIndividuals
2017
Prominent motor abnormalities in Thai men and women with presumed subtype CRF01_AE HIV-1 infection improve with antiretroviral therapy (P2.304)
Silverman A, Chan P, Paul R, Hellmuth J, Sithinamsuwan P, Ananworanich J, Phanuphak N, Fletcher J, Chalermchai T, Tipsuk S, Suttichom D, Valcour V, Spudich S. Prominent motor abnormalities in Thai men and women with presumed subtype CRF01_AE HIV-1 infection improve with antiretroviral therapy (P2.304). Neurology 2017, 88 DOI: 10.1212/wnl.88.16_supplement.p2.304.Peer-Reviewed Original Research
2016
50LB Central nervous system impact of vorinostat, hydroxychloroquine and maraviroc combination therapy followed by treatment interruption in individuals treated during acute HIV infection
Kroon E, Ananworanich J, Le L, Intasan J, Benjapornpong K, Pinyakorn S, Karnsomlap P, Tipsuk S, Rattanamanee S, Hellmuth J, Eamyoung P, Eubanks K, Yang H, Phanuphak N, Souza M, Valcour V, Spudich S, Groups S. 50LB Central nervous system impact of vorinostat, hydroxychloroquine and maraviroc combination therapy followed by treatment interruption in individuals treated during acute HIV infection. Journal Of Virus Eradication 2016, 2: 27. DOI: 10.1016/s2055-6640(20)30995-x.Peer-Reviewed Original Research
2015
CNS reservoirs for HIV: implications for eradication
Hellmuth J, Valcour V, Spudich S. CNS reservoirs for HIV: implications for eradication. Journal Of Virus Eradication 2015, 1: 67-71. PMID: 26430703, PMCID: PMC4586130, DOI: 10.1016/s2055-6640(20)30489-1.Peer-Reviewed Original Research
2014
Treatment of HIV in the CNS: Effects of Antiretroviral Therapy and the Promise of Non-Antiretroviral Therapeutics
Peluso MJ, Spudich S. Treatment of HIV in the CNS: Effects of Antiretroviral Therapy and the Promise of Non-Antiretroviral Therapeutics. Current HIV/AIDS Reports 2014, 11: 353-362. PMID: 25063356, DOI: 10.1007/s11904-014-0223-y.Peer-Reviewed Original ResearchConceptsCentral nervous systemAntiretroviral therapyNew neurologic abnormalitiesTrajectory of HIVAIDS dementia complexSpectrum of HIVTreatment of HIVPersistent handViral suppressionNeurologic manifestationsAsymptomatic diseaseHIV infectionNeurologic abnormalitiesNeurocognitive disordersNeurologic diseaseNeurocognitive dysfunctionTherapeutic modalitiesNervous systemHIVSevere impairmentTherapyDiseasePatientsDysfunctionPathophysiology
2013
An Example of Genetically Distinct HIV Type 1 Variants in Cerebrospinal Fluid and Plasma During Suppressive Therapy
Dahl V, Gisslen M, Hagberg L, Peterson J, Shao W, Spudich S, Price RW, Palmer S. An Example of Genetically Distinct HIV Type 1 Variants in Cerebrospinal Fluid and Plasma During Suppressive Therapy. The Journal Of Infectious Diseases 2013, 209: 1618-1622. PMID: 24338353, PMCID: PMC3997583, DOI: 10.1093/infdis/jit805.Peer-Reviewed Original ResearchConceptsCentral nervous systemSuppressive therapyTreatment initiationNervous systemPlasma sequencesHIV Type 1 VariantsHuman immunodeficiency virus type 1Immunodeficiency virus type 1Cerebrospinal fluid specimensType 1 variantsVirus type 1CSF sequencesViral persistenceHIV-1Cerebrospinal fluidFluid specimensTherapyType 1Virus replicationMajor causePlasma samplesCSFViral evolutionSubjectsLittle evidenceSingle-copy assay quantification of HIV-1 RNA in paired cerebrospinal fluid and plasma samples from elite controllers
Dahl V, Peterson J, Spudich S, Lee E, Shacklett BL, Price RW, Palmer S. Single-copy assay quantification of HIV-1 RNA in paired cerebrospinal fluid and plasma samples from elite controllers. AIDS 2013, 27: 1145-1149. PMID: 23211774, PMCID: PMC4004626, DOI: 10.1097/qad.0b013e32835cf235.Peer-Reviewed Original ResearchConceptsHIV-1 RNACentral nervous systemHIV-1 RNA quantificationElite controllersCerebrospinal fluidPlasma samplesCSF samplesHIV-1 RNA concentrationsHIV-1-infected individualsConcurrent plasma samplesSingle-copy assayRNA quantificationAntiretroviral therapyCopies/HIV-1Rare subsetNervous systemRNA concentrationClinical assaysSensitive assayAssaysRNATherapyInfectionBloodProgressive Increase in Cerebrospinal Fluid (CSF) Neopterin and Relation to Neuropsychological Performance during Primary HIV-1 Infection Prior to Antiretroviral Therapy (P06.189)
Suh J, Robertson K, Peterson J, Lee E, Kyriakides T, Li F, Fuchs D, Price R, Hagberg L, Gisslen M, Spudich S. Progressive Increase in Cerebrospinal Fluid (CSF) Neopterin and Relation to Neuropsychological Performance during Primary HIV-1 Infection Prior to Antiretroviral Therapy (P06.189). Neurology 2013, 80 DOI: 10.1212/wnl.80.7_supplement.p06.189.Peer-Reviewed Original Research
2012
HIV-1-Related Central Nervous System Disease: Current Issues in Pathogenesis, Diagnosis, and Treatment
Spudich S, González-Scarano F. HIV-1-Related Central Nervous System Disease: Current Issues in Pathogenesis, Diagnosis, and Treatment. Cold Spring Harbor Perspectives In Medicine 2012, 2: a007120. PMID: 22675662, PMCID: PMC3367536, DOI: 10.1101/cshperspect.a007120.Peer-Reviewed Original ResearchConceptsHIV infectionLate-stage HIV infectionCentral nervous system injuryOptimal antiretroviral therapyNeuropathogenesis of HIVTreatment of HIVNervous system injuryLong-term survivalAntiretroviral therapyCNS complicationsAntiretroviral medicationsViral neuroinvasionSystem injuryCNS injuryClinical studiesNeurological abnormalitiesUnderresourced settingsNeuropsychological testingHIVInfectionSubstantial proportionTherapyInjuryTreatmentCurrent eraNeurologic complications of HIV infection.
Spudich SS, Ances BM. Neurologic complications of HIV infection. Topics In Antiviral Medicine 2012, 20: 41-7. PMID: 22710906, PMCID: PMC6148861.Peer-Reviewed Original ResearchConceptsCentral nervous systemHIV infectionNervous systemBrain microglial activationWarrants further studyAntiretroviral therapyNeurologic complicationsMicroglial activationNeurologic impairmentOpportunistic infectionsClinical studiesEarly initiationNeurocognitive disordersHIV-1Neuropsychological testingHIVNormal agingOngoing abnormalitiesInfectionFurther studiesTherapyComplicationsNeuropathogenesisPoster presentationsAbnormalities